A
ARIAD Pharmaceuticals
ARIAD is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients
About ARIAD Pharmaceuticals
In 1991, Harvey J. Berger founded ARIAD Pharmaceuticals in Cambridge, Massachusetts, with a focus on discovering and developing medicines for cancer patients. The company made a significant entrance by raising $46 million in its initial financing in 1992, which at the time, was the largest single funding round in the biotechnology industry. This early success set the stage for ARIAD to go public with an IPO on NASDAQ in 1994. The company’s work centered on creating small-molecule drugs to treat various forms of cancer. Their key product, Iclusig, was developed to treat specific types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). ARIAD also had a promising investigational drug, brigatinib, in its pipeline for a specific form of non-small cell lung cancer. The major turning point for ARIAD came in January 2017, when Takeda Pharmaceutical Company announced it would acquire the company for approximately $5.2 billion. This acquisition was a strategic move for Takeda to expand its oncology and hematology portfolio. The deal was completed in February 2017, and ARIAD became an indirect wholly-owned subsidiary of Takeda, ceasing to trade on the NASDAQ. The acquisition integrated ARIAD's targeted therapies, Iclusig and the potential blockbuster brigatinib, into Takeda's global oncology business.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1991
- Headquarters
- Cambridge, United States
- Listing
- IPO 1994
- Employees
- 137
- Open positions
- None listed
- Dealroom signal
- 67.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, DNA, Genetics and genomics, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2c
- Investment activity
- 1 company, latest Jan 2018
- Capital deployed
- $22M
- Preferred round
- SERIES A
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2017 | $5.2B | $5.2B | Takeda | — |
| POST IPO EQUITYOther financing | Oct 2006 | $14M | — | Credit Suisse | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ARIAD Pharmaceuticals is 100 monthly website visits, down 56.5% over the last three months. ARIAD Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
BB Biotech- FVForward Ventures
- WVWellington Access Ventures
Avalon Ventures
Series B and later2 investors entered at this stage
- MBMerlin Biomed
Credit Suisse
Other known investors2 additional known investors
Takeda
Medicxi
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ARIAD Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ARIAD Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.